摘要
目的观察哌拉西林—他唑巴坦用于恶性血液病化疗后粒细胞缺乏合并感染经验性治疗的临床疗效及其不良反应。方法将73例恶性血液病化疗后粒细胞缺乏合并感染患者随机分为治疗组34例和对照组39例。治疗组予以哌拉西林—他唑巴坦4.5g静脉滴注,每6小时1次;对照组予以亚胺培南—西司他汀0.5g静脉滴注,每8小时1次。观察并比较2组临床疗效、细菌清除率及不良反应。结果治疗组有效率和细菌清除率分别为73.53%、74.07%,对照组分别为76.92%、76.67%,差异均无统计学意义(P>0.05)。治疗组一般不良反应和二重感染发生率分别为8.82%、5.88%,低于对照组的25.64%、25.64%,差异均有统计学意义(P<0.05)。结论哌拉西林—他唑巴坦与亚胺培南—西斯他汀相比疗效相似,但二重感染发生率低,可以作为恶性血液病化疗后粒细胞缺乏合并感染的一线经验性治疗方案。
Objective To evaluate the safety and efficacy of Piperacillin-Tazobatam on neutropenic febrile patients after receiveing the chemical treatment.Methods 73 cases of hematologic malignancies after chemotherapy granulocyte deficiency complicated with infection were randomly divided into treatment group(34 cases) and control group(39 cases).The treatment group received Piperacillin-Tazobactam 4.5g,intravenous infusion,every 6 hours for once;control group was treated with imipenem/cilastatin0.5g intravenous infusion,every 8 hours for 1 times.Clinical efficacy,bacterial eradication rates and adverse reaction in the two groups were observed.Results The effective rate and bacterial clearance rate in treatment group were 73.53% and 74.07%,and 76.92%,76.67% in control group,there were no significant differences between them(P>0.05).General adverse reactions and double infection rates in the treatment group were 8.82%,5.88% respectively,lower than the control group(25.64%,25.64%),the differences were statistically significant(P<0.05).Conclusion Efficacy of Piperacillin-Tazobactam is similar with imipenem-Sith statins,but has double low infection rate,can be used as hematologic malignancies after chemotherapy of neutropenia with first-line empiric treatment options.
出处
《临床合理用药杂志》
2012年第11期36-37,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
哌拉西林-他唑巴坦
恶性血液病
粒细胞缺乏合并感染
不良反应
二重感染
Piperacillin-Tazobatam
Malignant hematological disease
Neutropenia with infection
Adverse reaction
Double infection
